Skip to main content


Log in

Phase II Trial of Amonafide in Central Nervous System Tumors: A Southwest Oncology Group Study

  • Published:
Investigational New Drugs Aims and scope Submit manuscript


Amonafide 300 mg/M2 was administeredintravenously on a daily × 5 schedule to 27eligible patients with recurrent orprogressive central nervous system tumors. There were no objective responses. Themost common toxicities weregastrointestinal, hematologic andneurologic. Further study of amonafide inpatients with central nervous systemmalignancies is not indicated.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others


  1. Brana M, Sanz A, Castellano J, Roldan M, Roland C: Synthesis and cytostatic activity of benz (de)-isoquinolin-1,3-diones. Structure-activity relationships. Eur J Med Chem Clinica Therapeutics 16: 207–212, 1981

    Google Scholar 

  2. National Cancer Institute – Clinical Brochure, Nafidimide, NSC-308847, P. 10, November 1984

  3. Waring M, Gonzalez A, Jimenez A, Vazquez D: Intercalative binding to DNA of antitumor drugs derived from 3-nitro-1, 8-napthalic acid. Nucleic Acid Res 7: 217, 219

  4. Legha S, Ring S, Raber M, Felder TB, Newman RA, Krakoff IH: Phase I clinical investigation of benzisoquinolinedione. Cancer Treat Rep 7: 1165–1169, 1987

    Google Scholar 

  5. Miller A, Hoogstraten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer 47: 207–214 1981

    Google Scholar 

  6. Kaplan EL, Meier P: Nonparametric observation from incomplete observations. J Am Stat Assoc 53: 457–481, 1958

    Google Scholar 

  7. Levitt R, Buckner JC, Cascino TL, Burch PA, Morton RF, Westburg MU, Goldberg RM, Gallagher JG, O'Fallon JR, Scheithauser BW: Phase II study of amonafide in patients with recurrent glioma. J Neuro Oncol 23(1): 87–93, 1995

    Google Scholar 

  8. Malviya VK, Liu PY, O'Toole R, Alberts DS, Surwit E, Rosenoff S, Ward JH, Yu A, O'sullivan J, Craig J: Phase II trial of amonafide in patients with advanced metastatic or recurrent endometrial adenocarcinoma. A Southwest Oncology Group Study. Am J Clin Oncol 17(1): 37–40, 1994

    Google Scholar 

  9. Kornek G, Raderer M, Depisch D, Haider K, Fazeny B, Dittrich C, Scheithauer W: Amonafide as first line chemotherapy for metastatic breast cancer. Eur J Cancer 30A(3): 398–400, 1994

    Google Scholar 

  10. Gesme DH, Jett JR, Schreffler DD, Su JQ, Mailliard JA, Foley JF, Krook JE, Maksymiuk AW, Hatfield AK, Ebbert LP, Pfeifle DM, Morton RF, Tschetter LK, Schaefer PL: A randomized phase II trial of amonafide or trimetrexate in patients with advanced non small cell lung cancer. A trial of the North Central Cancer Treatment Group. Cancer. 71(9): 2723–2726, 1993

    Google Scholar 

Download references

Author information

Authors and Affiliations


Rights and permissions

Reprints and permissions

About this article

Cite this article

Taylor, S.A., Rankin, C., Townsend, J.J. et al. Phase II Trial of Amonafide in Central Nervous System Tumors: A Southwest Oncology Group Study. Invest New Drugs 20, 113–115 (2002).

Download citation

  • Issue Date:

  • DOI: